Independent radiologic review in metastatic colorectal cancer: Systematic review and meta-analysis

Radiology

Volumn 263, Issue 1, 2012, Pages 86-95

  Da Silveira Nogueira Lima, João Paulo ^a,b   De Souza, Fabiano Hahn ^c   De Andrade, Diocésio Alves Pinto ^d   Carvalheira, José Barreto Campello ^b   Dos Santos, Lucas Vieira ^a,b  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Department of Medical Oncology   (Brazil)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; EVALUATION BIAS; HUMAN; INDEPENDENT RADIOLOGIC REVIEW; INTERMETHOD COMPARISON; LOCAL RADIOLOGIC ASSESSMENT; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; OBJECTIVE RESPONSE RATE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; CHI SQUARE DISTRIBUTION; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; PATHOLOGY; SURVIVAL;

CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 84861321831     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11111111     Document Type: Review

References (72)

1. Dancey JE, Dodd LE, Ford R, et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer 2009;45(2):281-289.
2. Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE. Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer 2004;43(1):71-74. (Pubitemid 38096294)
3. Obuchowski NA. How many observers are needed in clinical studies of medical imaging? AJR Am J Roentgenol 2004;182(4):867-869. (Pubitemid 38391644)
4. Belton AL, Saini S, Liebermann K, Boland GW, Halpern EF. Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol 2003;58(4):311-314. (Pubitemid 36416974)
5. Barlési F, Balleyguier C, Besse B, et al. Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Ann Oncol 2010;21(8):1682-1686.
6. Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-oncol 2011;13(3):353-361.
7. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21(13):2574-2582. (Pubitemid 46606340)
8. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365(9465):1159-1162. (Pubitemid 40417566)
9. Gluud LL. Bias in clinical intervention research. Am J Epidemiol 2006;163(6):493-501.
10. Dodd LE, Korn EL, Freidlin B, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 2008;26(22):3791-3796.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207-214. (Pubitemid 11167383)
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
14. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. US Food and Drug Administration Website. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071590.pdf. Published May 2007. Accessed January 3, 2011.
15. Methodological considerations for using progression-free survival (PFS) as primary endpoint in confirmatory trials of registration. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en-GB/document-library/Other/ 2009/12/WC500017749.pdf. Published January 24, 2008. Accessed January 3, 2011.
16. Colorectal cancer endpoints workshop summary. US Food and Drug Administration Web site. http://www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDER/ucm120842.htm. Published April 30, 2009. Accessed January 3, 2011.
17. Ford R, Schwartz L, Dancey J, et al. Lessons learned from independent central review. Eur J Cancer 2009;45(2):268-274.
18. Tang PA, Pond GR, Chen EX. Influence of an independent review committee on assessment of response rate and progressionfree survival in phase III clinical trials. Ann Oncol 2010;21(1):19-26.
19. Stone AM, Bushnell W, Denne J, et al. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Eur J Cancer 2011;47(12):1763-1771.
20. Markman M. The myth of measurable disease in ovarian cancer. J Clin Oncol 2003;21(16):3013-3015. (Pubitemid 46606279)
21. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007;8(10):898-911. (Pubitemid 47488054)
22. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006;7(9):741-746. (Pubitemid 44283658)
23. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25(29):4562-4568. (Pubitemid 350035313)
24. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319(7211):670-674. (Pubitemid 29423954)
25. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. 2nd ed. London, England: BMJ Publication Group, 2001;189-210.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-188. (Pubitemid 17189972)
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003;327(7414):557-560.
28. Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Chichester, England: Wiley, 2008;243-296.
29. Van Cutsem E, Dirix L, Van Laethem JL, et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer 2005;92(6):1055-1062. (Pubitemid 40546669)
30. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-1664. (Pubitemid 46797944)
31. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19(21):4097-4106. (Pubitemid 33049527)
32. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209):1041-1047. (Pubitemid 30162806)
33. Punt CJ, Keizer HJ, Douma J, et al. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol 2002;13(1):81-86. (Pubitemid 34436729)
34. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21(7):1307-1312. (Pubitemid 46606408)
35. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002;20(1):165-172. (Pubitemid 34032608)
36. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000;18(6):1337-1345. (Pubitemid 30159854)
37. Bécouarn Y, Gamelin E, Coudert B, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001;19(22):4195-4201. (Pubitemid 33081636)
38. Bleiberg H, Vandebroek A, Deleu I, et al. Randomized phase II study of combined infusional leucovorin sodium (LVNa) and 5-FU versus the sequential administration of leucovorin calcium (LVCa) followed by 5-FU with irinotecan or oxaliplatin in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2010;28(suppl; abstr e14019). http://www.asco.org/ascov2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=74&abstractID=41775. Accessed December 18, 2010.
39. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27(5):663-671.
40. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26(12):2006-2012.
41. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337-345. (Pubitemid 38944402)
42. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938-2947. (Pubitemid 30644117)
43. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20(17):3605-3616. (Pubitemid 34983220)
44. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28(31):4697-4705.
45. Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011;128(3):682-690.
46. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as firstline treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670-1676. (Pubitemid 46797946)
47. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008;26(13):2099-2105.
48. Giacchetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chrono-modulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006;24(22):3562-3569. (Pubitemid 46630527)
49. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18(1):136-147. (Pubitemid 30036347)
50. Glimelius B, Sørbye H, Balteskard L, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008;19(5):909-914. (Pubitemid 351627306)
51. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27(5):672-680.
52. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19(8):2282-2292. (Pubitemid 32366981)
53. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-65.
54. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697-3705.
55. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19(10):1720-1726.
56. Rougier P, Lepille D, Bennouna J, et al. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 2002;13(10):1558-1567. (Pubitemid 35331453)
57. Scheithauer W, Kornek G, Marczell A, et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 1997;15(3):908-914. (Pubitemid 27106271)
58. Scheithauer W, Kornek GV, Brugger S, et al. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest 2002;20(1):60-68. (Pubitemid 34151060)
59. Ychou M, Hohenberger W, Thezenas S, et al. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301) [abstr]. J Clin Oncol 2008;26(15 Suppl):LBA4013.
60. Schoemaker NE, Kuppens IE, Moiseyenko V, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 2004;91(8):1434-1441.
61. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229-237. (Pubitemid 41095086)
62. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-1417.
63. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-2019.
64. Altman DG. Practical statistics for medical research. London, England: Chapman & Hall, 1990.
65. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219. (Pubitemid 36143396)
66. Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S. An audit strategy for progression-free survival. Biometrics 2011;67(3):1092-1099.
67. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 2005;23(28):6982-6991.
68. Gwyther SJ, Nielsen OS, Judson IR, van Glabbeke M, Verweij J. Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. Anticancer Drugs 2000;11(6):433-437.
69. Gwyther S, Bolis G, Gore M, et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol 1997;8(5):463-468.
70. Gwyther SJ, Aapro MS, Hatty SR, Postmus PE, Smith IE. Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer. Anticancer Drugs 1999;10(8):693-698. (Pubitemid 30015669)
71. Amit O, Mannino F, Stone AM, et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer 2011;47(12):1772-1778.
72. Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 2005;21(1):119-125. (Pubitemid 40229377)